Ascendis Pharma A/S Q1 2023 Earnings Report $138.18 -7.56 (-5.19%) As of 04:00 PM Eastern Earnings HistoryForecast Ascendis Pharma A/S EPS ResultsActual EPS-$2.12Consensus EPS -$2.84Beat/MissBeat by +$0.72One Year Ago EPSN/AAscendis Pharma A/S Revenue ResultsActual Revenue$36.04 millionExpected Revenue$24.53 millionBeat/MissBeat by +$11.51 millionYoY Revenue GrowthN/AAscendis Pharma A/S Announcement DetailsQuarterQ1 2023Date4/27/2023TimeN/AConference Call ResourcesPress ReleaseASND Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Ascendis Pharma A/S Earnings HeadlinesTD Cowen Sticks to Its Buy Rating for Ascendis Pharma (ASND)March 5, 2025 | markets.businessinsider.comAscendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Moderate Buy" by BrokeragesFebruary 28, 2025 | americanbankingnews.comTrump’s Tariff Horrors (your golden opportunity)With new tariffs on the way, millions of Americans are having nightmares about how much they'll have to spend. But here's the secret they're not talking about… A historic $72 trillion wealth transfer is already underway and it's creating a tidal wave of opportunity for people who know what to do.March 10, 2025 | Awesomely, LLC (Ad)Research Analysts Issue Forecasts for ASND FY2025 EarningsFebruary 28, 2025 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $200.00February 28, 2025 | americanbankingnews.comAscendis Pharma to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | markets.businessinsider.comSee More Ascendis Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email. Email Address About Ascendis Pharma A/SAscendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.View Ascendis Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Upcoming Earnings Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
